Search the Site


test tubes

BioRunUp Run-Up Valuation Report for MNKD Released

publication date: Oct 27, 2010
Today we are pleased to release our detailed 9 page report on MNKD and its run-up potential. This PDF report contains detailed analysis of the following:
MNKD's history
Drug market
Market share
Potential obstacles
Approval values with and without the approval of BIOD's Linjeta.
Approval values if MNKD receives a financial 'spotter' before the PDUFA date
This detailed analysis and run-up valuation is available for subscribers.  We also have detailed valuation reports for the following companies:
Benefits of a membership include:
- Detailed Reports on Upcoming FDA / Clinical Trades
- Analyst Reports with consistently updated summaries (Sample)
- Run-Up Valuation Studies (Sample)
- Weekly Newsletter (Sample)
- Email / SMS (Text Message) Alerts of critical news (Sample)
- A New Clinical Calendar (Sample)
- Screenshots of BioRunUp and mikehavRx's Trading Accounts
- BioRunUp Forums - A community of informed traders
- Merger with to offer combined service
- A More Detailed FDA Calendar, linked to PDF reports
- Historical FDA Tracker
- BioRunUp Live Newsfeed
- Spreadsheet download for clinical / regulatory catalyst calendar plus integrated Google Docs / Finance tracking
- Mike Havrilla's portfolio and stock watch list along with stock trades and performance stats
- Corporate Event Google Calendar tracking for bio-catalyst stocks
- Bio-Pharma, FDA, Clinical Trials, and Stock Market News Updates
- HavRx Healthcare Sub-Sector Indexes
- Increased Organization of Tracking Upcoming Catalysts
- A Unique Ratings System to Grade Catalysts
- A Growing Focus on Upcoming Clinical Trial Catalysts
- Direct Email Communication
- Affiliate Program, earn $50 for every referral who joins